Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.66 |
| ▸ | LMNA | P02545 | 2/20 | 0.66 |
| ▸ | HPGD | P15428 | 1/20 | 0.66 |
| ▸ | NAMPT | P43490 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | PDE2A | O00408 | 1/20 | 0.58 |
| ▸ | ATM | Q13315 | 1/20 | 0.57 |
| ▸ | BRD4 | O60885 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12172996 | 0.92 | HPGD (0.60) | SMN1; SMN2LMNAHPGDNAMPTALDH1A1 | |
| SCHEMBL12697047 | 0.88 | SMN1; SMN2 (0.64) | SMN1; SMN2LMNAHPGDMAPTL3MBTL1 | |
| SCHEMBL2919972 | 0.88 | SMN1; SMN2 (0.82) | SMN1; SMN2LMNAHPGDALDH1A1KDM4E | |
| SCHEMBL9543614 | 0.88 | MEN1 (0.67) | SMN1; SMN2LMNAHPGDALDH1A1KDM4E | |
| SCHEMBL4629469 | 0.87 | SMN1; SMN2 (0.52) | SMN1; SMN2LMNAHPGDNAMPTALDH1A1 | |
| SCHEMBL582322 | 0.85 | SMN1; SMN2 (0.85) | SMN1; SMN2LMNANAMPTALDH1A1L3MBTL1 | |
| SCHEMBL30474381 | 0.85 | APEX1 (0.55) | SMN1; SMN2LMNAHPGDNAMPTALDH1A1 | |
| SCHEMBL29200010 | 0.85 | APEX1 (0.55) | SMN1; SMN2LMNAHPGDNAMPTALDH1A1 | |
| SCHEMBL18560604 | 0.85 | SMN1; SMN2 (0.67) | SMN1; SMN2LMNAHPGDNAMPTALDH1A1 | |
| SCHEMBL14082197 | 0.84 | SMN1; SMN2 (0.57) | SMN1; SMN2LMNAHPGDNAMPTMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2001055107-A2 | AROMATIC AMINES AND AMIDES ACTING ON THE MELANOCORTIN RECEPTORS | MELACURE THERAPEUTICS AB (SE) | 2001-08-02 | — | — | WO | claimed |
| US-8530506-B2 | Process for production of biphenyl derivative | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-09-10 | — | — | US | disclosed |
| US-8530506-B2 | Process for production of biphenyl derivative | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-09-10 | — | — | US | disclosed |
| EP-2502919-A1 | PROCESS FOR PRODUCTION OF BIPHENYL DERIVATIVE | Mitsubishi Tanabe Pharma Corporation (JP) | 2012-09-26 | — | — | EP | disclosed |
| US-20120232283-A1 | PROCESS FOR PRODUCTION OF BIPHENYL DERIVATIVE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-09-13 | — | — | US | disclosed |
| WO-2011061996-A1 | PROCESS FOR PRODUCTION OF BIPHENYL DERIVATIVE | 田辺三菱製薬株式会社 (JP) | 2011-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232283-A1 | PROCESS FOR PRODUCTION OF BIPHENYL DERIVATIVE | AGTR2, AGTR1, ACE | SMN1; SMN2 4872/4885LMNA 3522/4885HPGD 1325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.